Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
RESEARCH TOOLSreports
Holding TEVA?
Track your performance easily
TEVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.48 - $22.80
Previous CloseN/A
Volume1.13M
Average Volume (3M)11.09M
Market Cap
$24.54B
Enterprise Value$36.69B
Total Cash (Recent Filing)$988.00M
Total Debt (Recent Filing)$32.52B
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Jan 29, 2025EPS Estimate
0.7Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding1,134,592,400
10 Day Avg. Volume9,960,903
30 Day Avg. Volume11,089,281
Standard Deviation0.11
R-Squared0.11
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.46
Price to Cash Flow (P/CF)8.90
P/FCF Ratio11.30
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue2.19
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda18.38
Forecast
1Y Price Target
$26.40Price Target Upside22.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Teva Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentInvestors focused on TEVA's recent positive Ph2 data for duvakitug (TL1a) in UC and Crohn’s, which could prompt further development in other fibrotic disorders.
Financial StrategyA TAPI deal in the range of $2-3 billion could accelerate the path to long-term leverage target and improve the financial standing of the company.
Product Growth DriversUS brands, mostly Austedo and Uzedy, are seen as TEVA’s biggest revenue growth drivers.
Bears Say
Earnings4Q is expected to be a soft quarter for US generics given TEVA recognizes negligible contribution from its largest generic, Revlimid.
Future Growth ChallengesTEVA discussed key medium-term portfolio drags, including the Gx Revlimid cliff in 2026 and Austedo IRA by 2027 or 2028, which could create growth headwinds.
Market CompetitionUncertain competitive dynamics flagged as a net pricing variable for g-Revlimid could affect the generics market.
---
Ownership Overview
0.42% Insiders
6.60% Mutual Funds
0.25% Other Institutional Investors
89.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $11.48 and its highest was $22.80 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Teva Pharmaceutical’s market cap is $24.54B.
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Jan 29, 2025 which is yesterday.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Nov 06, 2024. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.661 by $0.029.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is 0.7.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,134,592,400 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.69 in its last earnings report, beating expectations of $0.661. Following the earnings report the stock price went down -7.139%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Among the largest hedge funds holding Teva Pharmaceutical’s share is Slate Path Capital LP. It holds Teva Pharmaceutical’s shares valued at 246M.
---
Teva Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.40 (22.62% Upside)
$26.40 (22.62% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 81%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.11%
12-Months-Change
Fundamentals
Return on Equity
-16.36%
Trailing 12-Months
Asset Growth
-0.78%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
---
TEVA Company Deck
---
TEVA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment due to strong revenue growth, robust performance in innovative and generics segments, and improved financial metrics. Despite some challenges such as legal settlements and an operating loss, Teva's strategic execution and positive credit rating outlook suggest strong future potential.Read More>---
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
---
TEVA Stock 12 Month Forecast
Average Price Target
$26.40
▲(22.62% Upside)
Technical Analysis
Best Analysts Covering TEVA
1 Year
1 Year Success Rate
18/24 ratings generated profit
1 Year Average Return
+33.32%
assigned a buy rating 2 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +33.32% per trade.
---